department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Jascayd · pharmadog

pharmadog
drugs
Jascayd

drug · small molecule

patient view →

nerandomilast

Marketedupdated 2mo ago

by Boehringer Ingelheim International GmbH🔗 ChEMBL

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.

indications

investigational

Pulmonary Fibrosis

all catalysts(3)

approval · 3

News(0)

no news has mentioned this drug yet

brand

Jascayd

generic

nerandomilast

indication

Systemic Sclerosis (Scleroderma)

phase

marketed

JASCAYD (NERANDOMILAST) — FDA approval

JASCAYD (NERANDOMILAST) — FDA approval

JASCAYD (NERANDOMILAST) — FDA approval

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 19, 2028

~2.5 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

Oct 22, 2038method-of-use (U-4297)US 11406638
Oct 22, 2038method-of-use (U-4297)US 11406638
Oct 22, 2038method-of-use (U-4292)US 11813266
Oct 22, 2038method-of-use (U-4292)US 11813266
Feb 19, 2034method-of-use (U-4298)US 9802954
Feb 19, 2034method-of-use (U-4298)US 9802954
Aug 23, 2032compositionUS 8609670
Aug 23, 2032compositionUS 8609670
Nov 26, 2029compositionUS 87540733.4y
Nov 26, 2029compositionUS 87540733.4y

FDA exclusivities (4)

Oct 7, 2030NCENew Chemical Entity (5y)4.3y
Oct 7, 2030NCENew Chemical Entity (5y)4.3y
Dec 19, 2028I-979Indication (3y)2.5y
Dec 19, 2028I-979Indication (3y)2.5y

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 4

tagApproval12 co-mentions · 3 sources
drugJASCAYD12 co-mentions · 3 sources
companyBoehringer Ingelheim Corp6 co-mentions · 3 sources
tagSmall Molecule6 co-mentions · 3 sources

Trials studying nerandomilast

phase3A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseasesrecruitingn=400
phase3A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosisrecruitingn=80
phase3A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)not yet recruitingn=35
phase3A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosisnot yet recruitingn=448
phase3FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progressionnot yet recruitingn=466
phase3A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilastrecruitingn=1,700
phase2Platform Clinical Study for Conquering Sclerodermarecruitingn=400
phase1A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Foodcompletedn=15

more trials →